Preliminary experience with renal transplantation in HIV+ recipients: Low acute rejection and infection rates

Transplantation

Volumn 86, Issue 2, 2008, Pages 269-274

  Gruber, Scott A ^a,b   Doshi, Mona D ^a   Cincotta, Elizabeth ^b   Brown, Kristian L ^a   Singh, Atul ^a   Morawski, Katherina ^a   Alangaden, George ^a   Chandrasekar, Pranatharthi ^a   Losanoff, Julian E ^a   West, Miguel S ^a   El Amm, Jose M ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

Acute rejection; Human immunodeficiency virus; Renal transplantation

Indexed keywords

ANTIBIOTIC AGENT; BASILIXIMAB; COTRIMOXAZOLE; CYCLOSPORIN A; DACLIZUMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEVIRAPINE; NYSTATIN; PREDNISONE; RAPAMYCIN; RITONAVIR; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; INTERLEUKIN 2 RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AFRICAN AMERICAN; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONCENTRATION (PARAMETERS); DELAYED GRAFT FUNCTION; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INFECTION RATE; KIDNEY ALLOGRAFT REJECTION; KIDNEY DONOR; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; SENSITIZATION; URINARY TRACT INFECTION; VIRUS REPLICATION; CHEMISTRY; GRAFT REJECTION; HEPATITIS C; KIDNEY FAILURE; METHODOLOGY; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS C; HIV INFECTIONS; HUMANS; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2; RISK FACTORS; TREATMENT OUTCOME;

EID: 49249116364     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318177884e     Document Type: Article

References (22)

1. Stock PG, Roland ME, Carlson L, et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: A pilot safety and efficacy study. Transplantation2003; 76: 370.
2. Tan HP, Kaczorowski DJ, Basu A, et al. Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: A single center preliminary experience. Transplantation2004; 78: 1683.
3. Kumar MS, Sierka DR, Damask AM, et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int 2005; 67: 1622.
4. + T-cell depletion and infection risk in HIV-infected renal transplant recipients. Am J Transplant2006; 6: 753.
5. Trullas JC, Cofan F, Cocchi S, et al. Effect of thymoglobulin induction on HIV-infected renal transplant recipients: Differences between HIV-positive and HIV-negative patients. AIDS Res Hum Retroviruses 2007; 23: 1161.
6. Haririan A, Sillix DH, Morawski K, et al. Short-term experience with early steroid withdrawal in African-American renal transplant recipients. Am J Transplant2006; 6: 2396.
7. Frassetto L, Baluom M, Jacobsen W, et al. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation2005; 80: 13.
8. Frassetto LA, Browne M, Cheng A, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant2007; 7: 2816.
9. Roland ME. Solid-organ transplantation in HIV-infected patients in the potent antiretroviral therapy era. Top HIV Med 2004; 12: 73.
10. Mazuecos A, Pascual J, Gómez E, et al. Renal transplantation in HIV-infected patients in Spain. Nefrología 2006; 26: 113.
11. Qiu J, Terasaki PI, Waki K, et al. HIV-positive renal recipients can achieve survival rates similar to those of HIV-negative patients. Transplantation2006; 81: 1658.
12. Roland ME, Barin B, Carlson L, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant2008; 8: 355.
13. van Gelder T, Klupp J, Barten MJ, et al. Co-αdministration of tacrolimus and mycophenolate mofetil does not increase mycophenolic acid (MPA) exposure, but co-αdministration of cyclosporine inhibits the enterohepatic recirculation of MPA, thereby decreasing its exposure. J Heart Lung Transplant 2001; 20: 160.
14. Cremers S, Schoemaker R, Scholten E, et al. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by phar-macokinetic modelling. Br J Clin Pharmacol 2005; 60: 249.
15. Arns W, Cibrik DM, Walker RG, et al. Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with my-cophenolate mofetil: Review of the literature. Transplantation2006; 82: 1004.
16. Johnson AG, Rigby RJ, Taylor PJ, et al. The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients. Clin Pharmacol Ther 1999; 66: 492.
17. Shaw LM, Holt DW, Oellerich M, et al. Current issues in therapeutic drug monitoring of mycophenolic acid: Report of a roundtable discussion. Ther Drug Monit 2001; 23: 305.
18. Pawinski T, Durlik M, Szlaska I, et al. The weight of pharmacokinetic parameters for mycophenolic acid in prediction of rejection outcome: The receiver operating characteristic curve analysis. Transplant Proc 2006; 38: 86.
19. Pawinski T, Durlik M, Szlaska I, et al. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant. J Clin Pharm Ther 2006; 31: 27.
20. Jeong H, Kaplan B. Therapeutic monitoring of mycophenolate mofetil. Clin J Am Soc Nephrol 2007; 2: 184.
21. van Gelder T, Le Meur Y, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006; 28: 145.
22. Brown KL, El-Amm JM, Doshi MD, et al. Intermediate-term outcomes of hepatitis C+ versus hepatitis C - deceased-donor renal allograft recipients. Am J Surg 2008; 195:298.